Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.

8 In another phase 3 study ( NCT00337103 ), eribulin-treated patients did not have a significant improvement in OS as compared to patients treated with capecitabine in the first, second, or third line of chemotherapy in the metastatic setting, although a numerical trend favoring eribulin was demonstrated. 9 Interestingly, in a subsequent pooled analysis of both of these trials, eribulin was seen to have a significant improvement in OS, as compared to the control arm.

also in 337 other papers